Monthly information regarding the total number of voting rights and total number of shares of the Company as of June 30, 2023
(Article 223-16 of the General Regulations of the Autorité des Marchés Financiers)
Market : NYSE Euronext Paris
ISIN Code: FR 0010417345
| Date | Total number of shares | Total number of voting rights |
| 06/30/2023 | 96,250,954 | Total gross of voting rights: 96,250,954 |
| Total net* of voting rights: 96,100,982 |
* Net total = total number of voting rights attached to shares – shares without voting rights = 96,250,954 –149,972= 96,100,982
| Last Trade: | US$5.21 |
| Daily Change: | 0.33 6.76 |
| Daily Volume: | 47,687 |
| Market Cap: | US$106.910M |
January 08, 2025 December 11, 2024 November 06, 2024 October 22, 2024 September 23, 2024 | |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
